Vial format
Choose your peptide.
What is being studied
| Reference | Strength | Level of data | What is being studied |
|---|---|---|---|
| GHK-Cu | 50 mg · 100 mg | Early human data | SkinCollagenSkin repairSkin appearanceHair |
| Retatrutide | 10 mg · 15 mg · 20 mg · 30 mg · 60 mg | Clinical data | Weight lossBody shapeAppetite controlSatietyControl over eatingMetabolismBlood sugarDigestion |
| TB-500 | 10 mg | Preclinical | Tissue repairRecoveryCell movement |
| IGF-1 LR3 | 1 mg | Mechanistic | Cell cultureCell growthMetabolism |
| BPC-157 | 10 mg | Preclinical | Wound healingRecoveryTendons and musclesDigestion |
| CJC-1295 sans DAC | 10 mg | Early human data | The body’s own signalsRelease rhythmDuration of action |
| Ipamorelin | 10 mg | Early human data | Hunger signalPrecision of actionThe body’s own signals |
| MOTS-c | 10 mg · 40 mg | Mechanistic | MetabolismBlood sugarBody composition |
These are the areas the available literature has actually explored. A publication appears here only once it has been reopened at its original source and verified — never before.